The pyramidal lobe is a remnant of the thyroglossal duct and is considered a normal component of the thyroid gland. The pyramidal lobe may be affected by the diseases that affect the rest of the thyroid parenchyma. A practicing endocrine surgeon should keep the anatomical variations of the pyramidal lobe in mind to achieve a completely total thyroidectomy, when indicated. This approach is espec...

BACKGROUND The aim of this prospective randomized study was to evaluate the feasibility of subtotal thyroidectomy with leaving a unilateral remnant based on the upper pole. METHODS Patients who underwent the subtotal thyroidectomy and isthmusectomy leaving either a unilateral remnant based on the upper pole (Group I, 79 patients) or the bilateral dorsal thyroid tissue remained (Group II, 89 p...

Completion thyroidectomy is performed because of a deferred diagnosis of differentiated carcinoma of the thyroid or a significant thyroid remnant after initial operation. During a period of 6 years, data from 40 patients with differentiated thyroid carcinoma undergoing completion thyroidectomy were retrospectively reviewed. There were 4 men and 36 women (1:9), and the average age was 39.6+/-1.9...

The initial treatment of differentiated thyroid cancer (DTC) is thyroidectomy, followed by remnant ablation with radioiodine (I-131). However, substantial uncertainty persists over the indications and optimal dose for I-131. In addition, the usefulness of a follow-up diagnostic I-131 whole-body scan (WBS) performed within 6 to 12 months after initial therapy is controversial [1]. Although a dia...

Objectives: Radioiodine ablation for the treatment of thyroid cancer is traditionally performed after preparing patients by inducing hypothyroidism. Exogenous stimulation of thyroid-stimulating hormone (TSH) using recombinant human TSH (rhTSH) avoids hypothyroidism and hastens the clearance of radioiodine from the patient. These advantages are achieved without jeopardizing the success rate of r...

OBJECTIVE Remnant ablation with radioactive iodine (I-131) is a successful form of treatment that aims to destroy the remaining residual tissue and/or metastatic tissue after total thyroidectomy in differentiated thyroid cancer (DTC) patients. High level of thyroid stimulating hormone (TSH) (≥30 mIU/L) is recommended for success of ablation treatment. In this retrospective study, our aim was to...

The aim of this study is to investigate the possibility of determining the appropriate amount of thyroid tissue to leave behind as remnant weight in subtotal thyroidectomy for Graves' disease by measuring the TBII value, and correlating the outcome to the grade of intrathyroidal lymphocyte infiltration. We therefore have investigated the levels of TBII in the thyroidal (T-TBII) and peripheral (...

Remnant thyroid ablation after thyroidectomy with radioiodine (RAI, I-131) is considered the standard of care for low risk patients with well-differentiated thyroid cancer (WDTC). The choice of activity for therapy is usually empirically determined according to the tumor characteristics and the patient’s age. Many guidelines recommend a range of 1.1 to 3.7 GBq (30 to 100 mCi), although the choi...

Surgery remains the mainstay for treatment of differentiated thyroid carcinoma. Total or near-total thyroidectomy followed by radioiodine (I-131) ablation of residual thyroid tissue is the recommended treatment for high-risk disease, including those patients with macroscopic tumor invasion and distant metastases [1]. However, total or near-total thyroidectomy is not always possible, especially ...

OBJECTIVES The rate and impact of thyroglossal duct remnant (TGDR) visualization in patients with hypothyroidism after total thyroidectomy for differentiated thyroid carcinoma (DTC) have not yet been fully determined. The aim of this study was to assess the rate of TGDR visualization in post total thyroidectomy whole body scan (WBS) for DTC and to evaluate its impact on the outcome of I-131 abl...